Lamivudine Sandoz

Lamivudine, the active ingredient in Lamivudine Sandoz, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as a tablet for oral use. It is used to treat HIV infection and chronic hepatitis B in adults and adolescents.

GNH USA supplies Lamivudine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable delivery timelines, comprehensive documentation, and responsive technical support throughout the procurement process.

Lamivudine is indicated for viral infections where reverse transcriptase activity is essential.

- Human Immunodeficiency Virus (HIV) infection: reduces viral load and improves immune function in infected individuals. - Chronic Hepatitis B infection: suppresses viral replication and helps prevent disease progression.

Lamivudine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset often occurring early in therapy. - Headache: transient headache reported by some patients. - Fatigue: general tiredness without specific cause. - Diarrhea: loose stools that are usually self‑limiting.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal buildup of lactate requiring immediate medical attention. - Severe hepatotoxicity: marked liver enzyme elevation or liver failure. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and elevated enzymes.

When prescribing Lamivudine, clinicians should consider several precautionary measures to ensure safe use.

- Renal function: assess baseline kidney function and adjust dosing in severe impairment. - Hepatic disease: monitor liver enzymes regularly in patients with existing liver conditions. - Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited. - Concomitant antiretrovirals: evaluate for additive toxicities when combined with other NRTIs. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Lamivudine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis and mitochondrial toxicity. - Zidovudine: combined therapy may enhance bone marrow suppression.

Moderate Interactions (Monitor Closely): - Tenofovir: may increase renal toxicity; monitor renal function. - Rifampicin: can reduce lamivudine plasma levels; consider dose adjustment.